AMGN ▲ +5.0% - Amgen Inc. $AMGN AMGN - AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE Amgen shares rose 5.0% following the company's announcement of positive Phase 3 topline results for dazodalibep in moderate-to-severe systemic Sjögren's disease, a significant milestone that validates the drug candidate's potential in treating this autoimmune condition. The successful trial outcome de-risks the development program and opens a pathway toward a potential new treatment option in an underserved patient population. 22-SEP-2026 09:02 AM ET